THEON to Acquire HGH for €300M, Boosting Multi-Domain ISR and Counter-UAS Capabilities
Event summary
- THEON enters exclusivity agreement to acquire HGH for €300M enterprise value.
- HGH specializes in electro-optical and infrared solutions with 30% CAGR revenue growth since 2023.
- Acquisition expected to close by Q4 2026, financed via bridge facility from BNP Paribas.
- HGH's order backlog stands at €70M with EBITDA margin exceeding 40%.
- THEON aims to expand Multi-Domain ISR and Counter-UAS capabilities with this acquisition.
The big picture
THEON's acquisition of HGH aligns with its strategy to become a European leader in defense electro-optics, following recent investments in ShockEOS and a joint venture with Safran. The deal underscores a broader industry trend of consolidation in the defense sector, driven by the need for advanced ISR and Counter-UAS solutions. With HGH's proprietary AI-driven technology, THEON aims to enhance its situational awareness and decision-making capabilities for customers globally.
What we're watching
- Integration Challenges
- How THEON will merge HGH's R&D capabilities with its existing operations to achieve run-rate synergies by year 2 to 3.
- Market Expansion
- Whether THEON can leverage HGH's French base to strengthen its position in the European defense market.
- Regulatory Approvals
- The pace at which THEON secures necessary regulatory approvals to close the deal by Q4 2026.
Related topics